Compounded medications referenced in this article - including compounded semaglutide and compounded tirzepatide - are not FDA-approved finished drug products and have not been reviewed by the FDA for safety, effectiveness, or quality before marketing
These results potentially demonstrate a role of GLP-1 in preferentially acting on the liver and inducing hepatic glucose disposal and glycogenesis over that of skeletal muscle, given that endogenous GLP-1 is normally secreted in response to nutrient absorption following a fed state
Peter Rossing confirms that permission has been obtained from all acknowledged below
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the Western hemisphere, affecting 20% to 30% of the adult population [1]
In this piece, I look at whether biomimetic GLP-1 supplements, using Evolv as a case study, can deliver meaningful, compliant, and affordable appetite support at consumer price points, and what that would mean for the food industry
If you have been trying to understand the difference between Ozempic, Wegovy, and Zepbound, you are not alone
